Company intelligence / Profile preview
THOR Biopharma
Daejeon, South Koreathortherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pipeline under development with novel monoclonal antibodies and antisense oligonucleotides targeting metabolic complications in cancer and orphan/rare diseases; collaborations with KAIST researchers on cancer cachexia and MIF-CD74 interactions.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntisense oligonucleotide
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
KAIST (Dr. Ho Min Kim)KAIST (Dr. Jin Kuk Kim)
Beyond the preview
Go deeper on THOR Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THOR Biopharma.